ENKTL Clinical Trials

This Phase 3 trial is comparing XNW5004 ; Chidamide placebo and XNW5004 placebo; Chidamide against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 3 trial is comparing Sugemalimab, Placebo, and other medications against other options for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with NK/T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 3 trial is comparing Golidocitinib, Chidamide, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with NK/T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 11 US locations across multiple states.

This Phase 3 trial is comparing TR115 and Investigator's Choice against other options for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with NK/T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is studying DR-01 for people with enteropathy-associated T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 15 US locations across multiple states.

This Phase 2 trial is testing BR101801 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is testing GFH009 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is testing HH2853 Tablets for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 2 trial is evaluating Chidamide as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is comparing Azacytidine, Romidepsin, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 6 US locations across multiple states.

This Phase 2 trial is comparing ATL-RIC, mRIC, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 2 US locations.

This Phase 1, Phase 2 trial is comparing Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 2 trial is evaluating Golidocitinib, Cyclophosphamide, and other medications as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

This Phase 1, Phase 2 trial is comparing CCS1477, Pomalidomide, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 6 US locations across multiple states.

This Phase 1, Phase 2 trial is comparing STP938 against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 3 US locations.

This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 2 trial is testing XNW5004 tablets for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is testing Genetic: MB-105 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 12 US locations across multiple states.

This Phase 1, Phase 2 trial is testing Adebrelimab & SHR2554 for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with NK/T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 2 trial is evaluating JAK1 Inhibitor as a treatment for people newly diagnosed with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Immunochemotherapy as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Zeprumetostat, Azacitidine (AZA), and other medications as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Golidocitinib and CHOP Regimen as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 2 trial is testing PD-1 antibody+ HDAC inhibitor for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with NK/T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is evaluating Mitoxantrone Hydrochloride Liposome & Enlonstobart as a treatment for people newly diagnosed with T-cell lymphoma. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is studying Mitoxantrone liposome, Etoposide, and other medications for people with NK/T-cell lymphoma. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 2 trial is studying DAPT regimen plus radiotherapy for people with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is testing Golidocitinib and Benmelstobart for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Busulfan and Fludarabine as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Golidocitinib and Golidocitinib plus CHOP as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is testing Golicitinib combined with Pomadomide for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is evaluating Golidocitinib plus CHOP as a treatment for people newly diagnosed with T-cell lymphoma. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 2 trial is testing Pembrolizumab IV infusion Q3W and with daily oral Olaparib. for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Duvelisib and Chidamide as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is comparing roginolisib, golcadomide, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is evaluating Linperlisib in combination with CHOP as a treatment for people newly diagnosed with T-cell lymphoma. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 2 trial is studying Pegaspargase (PEG) Asparaginase, Gemcitabine (GEM), and other medications for people with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is testing Selinexor and azacitidine for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Golidocitinib + Pegaspargase + Anti-PD-1 mAb as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Thiotepa as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2, Phase 3 trial is testing Cidabenamine and Azacitidine for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is comparing tislezumab, golidocitinib, and other medications against other options for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is evaluating Linperlisib, Camrelizumab, and other medications as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 2 trial is evaluating Sintilimab, Pegaspargase, and other medications as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with NK/T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 2 trial is evaluating XPO1 inhibitor as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is testing golidocitinib and GEMOX for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is testing Linperlisib and Chidamide for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is comparing Tislelizumab and Zeprumetostat against other options for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 2 trial is studying Sintilimab+Pegaspargase, P-GemOx, and other medications for people with NK/T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is comparing chidamide and golidocitinib against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is testing Golidocitinib, Mitoxantrone Hydrochloride Liposome, and other medications for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 2 trial is evaluating CMOEP as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Chidamide combined with Duvillisib as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is studying reduced-intensity radiotherapy for people with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is testing Thiotepa for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating SHR2554 Tablets as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is testing Azacytidine plus CAOLD regimen for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 2 trial is testing SHR-0302 and SHR-2554 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Anti-PD-1 monoclonal antibody, Lenalidomide, and other medications as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Tislelizumab as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 2 trial is evaluating Chidamide combined with CHOP and Chidamide as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 1, Phase 2 trial is testing CD5/CD7 CAR-T for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This trial is studying Optional Blood Sample and Nail Sample for people with a type of T-cell lymphoma called AITL. The study measures how well this treatment works and monitors for side effects. It is widely available at 26 US locations.

This NA trial is comparing different first-line treatment approaches for people newly diagnosed with a type of T-cell lymphoma called AITL. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This Early Phase 1 trial is evaluating EBV TCR-T as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Early Phase 1 trial is comparing different first-line treatment approaches for people newly diagnosed with anaplastic large cell lymphoma (ALCL). Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 6 US locations across multiple states.

This Phase 1 trial is testing C7R.CD30.CAR-EBVST cells for people whose ALK-negative ALCL has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 2 US locations.

This trial is evaluating a new treatment as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This trial is evaluating a new treatment as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

This trial is evaluating Autologous Hematopoietic Stem Cell Transplantation and Allogenic stem cell transplant (ASCT) as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 1 trial is testing linperlisib and SHR2554 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This Phase 1 trial is testing Anti-TRBC1 CAR-T cells for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This NA trial is evaluating 4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase, and other medications as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This NA trial is evaluating Positron Emission Tomography/Magnetic Resonance (PET/MR) as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This trial is studying a new treatment for people with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This NA trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This NA trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

This trial is evaluating Observational as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This NA trial is evaluating SCA Induction followed by Response-Adapted Therapy as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Phase 1 trial is testing CD30.CAR-EBVST cells for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 2 US locations.

This Phase 1 trial is testing Ruxolitinib and Duvelisib for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 9 US locations across multiple states.

This Phase 1 trial is testing Sintilimab and Linperlisib Combination Treatment for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

This trial is evaluating Autologous Hematopoietic Stem Cell Transplantation and Observation as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This trial is evaluating Allogenic stem cell transplant (ASCT) and Salvage Therapy as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

This Early Phase 1 trial is evaluating Azacitidine (AZA) as a treatment for people newly diagnosed with T-cell lymphoma. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.